Beyond Probability: A New Framework to Rebuild Personalized Medicine

SALT LAKE CITY, UT – April 30, 2026 – In an ambitious challenge to the foundations of modern genomics, technologist and biology researcher Matthew L. Hardy has unveiled a new framework that seeks to reframe our understanding of complex disease, drug response, and human health. The proposal arrived with the announcement of his new book, “Deterministic Convergence: Biological Systems, Architecture, and the Search for Hidden Order.”

At its core, the book argues that the era of big data in biology has led to a critical misstep. While genomics has become exceptionally skilled at identifying the countless biological parts—genes, proteins, and biomarkers—it has struggled to explain how they assemble and function as a coherent system. This gap, which Hardy terms the “fragmentation error,” has become a significant bottleneck for the promise of personalized medicine.

Hardy, the Founder and CEO of the personalized medicine infrastructure company NomosLogic Inc., proposes a shift in perspective: from seeing biology as a game of probability to understanding it as a problem of architecture. The book and the company are built on this singular vision, one that could have profound implications for how we diagnose illness, design drugs, and define individual health.

The 'Fragmentation Error': Acknowledging a Genomic Blind Spot

For decades, the promise of genomics has been tantalizingly simple: sequence a person’s DNA to predict their disease risk and tailor treatments accordingly. Yet for most complex, multi-gene diseases like diabetes, heart disease, and autoimmune disorders, this promise has remained largely unfulfilled. The field has produced vast lists of genetic variants associated with slight increases in risk, but these probabilistic scores often lack direct clinical utility and fail to explain why one person with a specific risk profile gets sick while another remains healthy.

This is the essence of the “fragmentation error” Hardy describes. The scientific community has long recognized this challenge. Research is rife with discussions about the difficulty of translating massive genomic datasets into actionable clinical insights. The jump from identifying a genetic variant to understanding its role in a dynamic, living system is a chasm that statistical association alone cannot bridge. Current methods have proven effective for monogenic diseases, where a single faulty gene is the primary culprit, but they falter against the intricate web of interactions that define complex conditions.

“Probability tells you what to believe. Mechanism tells you what to do,” Hardy stated in the announcement, capturing the distinction between a risk score and a functional explanation. His framework argues that treating biology as a list of fragmented parts overlooks the rules of its assembly. It’s the difference between having a list of all the components in an airplane and having the actual blueprint that explains how they work together to achieve flight.

A New Blueprint: The Principle of Deterministic Convergence

Hardy's proposed solution is a principle he calls “Deterministic Convergence,” defined as the reproducible emergence of stable interaction structures under identical computational conditions. Rather than treating the complexity and variability in biological systems as random noise to be averaged away in large population studies, his approach argues for examining it as a source of order. The framework suggests that by analyzing the system’s architecture, one can understand its boundaries of stability and predict how it will behave under stress.

This architectural view is further illuminated by a concept introduced in the book called “The Adaptation Paradox.” This thesis posits that biological features evolved to protect a system under one set of conditions can become its greatest vulnerability under another. For example, a hyper-efficient immune response that is advantageous against pathogens might become a liability in the modern world, contributing to autoimmune disease. In this view, disease is not a random failure but an architectural behavior shaped by constraints, environment, and history.

While the terminology is new, the underlying quest for a more holistic understanding aligns with the broader scientific discipline of systems biology. For years, systems biologists have worked to model the complex interplay of biological components, moving beyond the reductionist focus on single genes. Hardy’s work aims to provide a specific, actionable framework to apply this systems-level thinking directly to genomic interpretation for personalized medicine, offering a structured way to find the hidden order in what appears to be chaos.

From Theory to Practice: Implications for Health and Medicine

The shift from a probability-based to an architecture-centered model could fundamentally alter clinical practice. For patients, it could mean moving beyond generic risk assessments toward a truly personalized understanding of their unique biology. Instead of being told they have a 15% higher risk for a certain condition, they might receive an analysis of their system’s specific vulnerabilities and resilience factors, leading to highly tailored preventative strategies or treatments.

This has major implications for drug discovery and development. Many drugs fail in clinical trials because they target a single component without accounting for the complexity of the system, leading to unexpected side effects or lack of efficacy across different populations. An architectural approach could enable the design of therapeutics that modulate the system’s behavior rather than just switching a single gene or protein on or off. This could be particularly transformative for complex diseases where single-target drugs have consistently failed.

Furthermore, the framework’s emphasis on interpreting biology with an awareness of ancestry and system history could help address known disparities in medicine. Current genomic models are largely based on data from European populations, limiting their applicability to individuals of other ancestries. By focusing on universal architectural principles that are shaped by specific ancestral histories, this approach may offer a more equitable and accurate path forward for global personalized medicine.

Building the Engine: The Vision Behind NomosLogic

“Deterministic Convergence” is not just an academic exercise; it is the foundational philosophy of NomosLogic. Hardy is positioning his company to build the computational infrastructure needed to make architecture-centered interpretation a reality. The company’s mission is to move beyond the fragmented analysis of variant lists and risk scores toward a system-level understanding of disease, resilience, and individualized therapeutic response.

The book’s release serves as a public declaration of this mission, aiming to establish the framework’s principles within the scientific and biotech communities. The personalized medicine market is a multi-billion dollar industry in the midst of what some analysts call a “Convergence Decade,” where advancements in AI, genomics, and digital health are rapidly transforming healthcare. NomosLogic is entering this competitive landscape with a bold claim: that it holds a key to unlocking the next frontier.

While specific details on NomosLogic’s proprietary tools and partnerships remain under wraps, the strategy is clear. By first establishing the intellectual framework, Hardy is building a foundation for a new category of diagnostic and therapeutic tools. The success of this venture will depend on whether this architectural vision can be translated into robust, scalable technology that delivers on its promise of a deeper, more functional understanding of human biology.

“Deterministic Convergence is not a rejection of genomics,” Hardy clarified. “It is an argument that genomics requires an architectural layer. We have become very good at identifying parts. The next frontier is understanding the system those parts create.”